Chromogenic in situ hybridization (CISH): A novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

Breast Cancer Research

Volumn 6, Issue 5, 2004, Pages

  Madrid, Manuelito A ^a   Lo, Raymundo W ^a  

^a Institute of Pathology   (Philippines)

Author keywords

Breast cancer; Chromogenic in situ hybridization; Fluorescence in situ hybridization; Her 2 neu; Immunohistochemistry

Indexed keywords

TRASTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SCREENING; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PHILIPPINES; PREMENOPAUSE; PRIMARY TUMOR; BREAST TUMOR; GENETICS; METABOLISM; METHODOLOGY; NUCLEIC ACID AMPLIFICATION; PATHOLOGY; PROTO ONCOGENE;

BREAST NEOPLASMS; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RECEPTOR, ERBB-2;

EID: 4644219811     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr915     Document Type: Article

References (35)

1. Popescu NC, King CR, Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989, 4: 362-366.
2. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of c-erbB-2 gene. A 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986, 232: 1644-1646.
3. Ross JS, Fletcher JA: HER-2/neu (C-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 1999, 112: 53-67.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 1987, 235: 177-182.
5. Sjogren S, Inganas M, Lingren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998, 16: 462-469.
6. Borg A, Baldetorp B, Ferno M, Kilander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett. 1994, 81: 137-144. 10.1016/0304-3835(94)90194-5.
7. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, DePlacido S: c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996, 14: 2702-2708.
8. Tetu B, Brisson J, Plante V, Bernard P: p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol. 1998, 11: 823-830.
9. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17: 2639-2348.
10. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining Her-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999, 17: 1983-1987.
11. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy; apparent immunohistochemical false-positive do not get the message. J Clin Oncol. 2001, 19: 2714-2721.
12. Park K, Kim J, Lim S, Han S, Lee JY: Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the Her2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003, 26: 937-943. 10.1097/01.MP.0000086487.78558.7D.
13. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I. The value of histologic grade in breast cancer - experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-310.
14. Corbett IP, Henry JA, Angus B, Watchorn CJ, Wilkinson L, Hennessy C, Gullick WJ, Tuzi NL, May FE, Westley BR, et al: NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. J Pathol. 1990, 161: 15-25.
15. Press MF, Hung G, Godolphin G, Slamon DJ: Sensitivity of Her-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994, 54: 2771-2777.
16. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL: Her-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001, 14: 1079-1086. 10.1038/modpathol.3880440.
17. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X: Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (Her-2/neu) gene status in breast carcinoma. Mod Pathol. 2000, 13: 1238-1243. 10.1038/modpathol.3880228.
18. Jimenez RE, Wallis T, Tabasczka P, Visscher DW: Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2000, 13: 37-45. 10.1038/modpathol.3880007.
19. Pauletti G, Godolphin W, Press MF: Detection and quantification of Her2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996, 13: 63-72.
20. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML: Her-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn. 2000, 5: 199-207. 10.1054/modi.2000.16690.
21. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, Isola J: Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000, 157: 1467-1472.
22. Kumamoto H, Sasano H, Taniguchi T, Suzuki T, Moriya T, Ichinohasama R: Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy. Pathol Int. 2001, 51: 579-584. 10.1046/j.1440-1827.2001.01255.x.
23. Dandachi N, Dietze O, Hauser-Kronberger C: Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002, 82: 1007-1014.
24. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z: Determination of Her2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002, 15: 657-665. 10.1038/modpathol.3880582.
25. Gupta D, Middleton LP, Whitaker MJ, Abrams J: Comparison of fluorescence and chromogenic in situ hybridization for detection of Her-2/neu oncogene in breast cancer. Am J Clin Pathol. 2003, 119: 381-387.
26. Arnould L, Denoux Y, MacGrogan G, Penault-Llorca F, Fiche M, Treilleux I, Mathieu MC, Vincent-Salomon A, Vilain MO, Couturier J: Agreement between chromogenic in situ hybridization (CISH) and FISH in the determination of Her2 status in breast cancer. Br J Cancer. 2003, 88: 1587-1591. 10.1038/sj.bjc.6600943.
27. Park K, Kim J, Lim S, Han S, Lee JY: Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the Her2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003, 26: 937-943. 10.1097/01.MP.0000086487.78558.7D.
28. Vera-Roman JM, Rubio-Martinez LA: Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med. 2004, 128: 627-633.
29. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN: Her-2/neu testing in breast cancer. Pathol Patterns Rev. 2003, 120: 53-71.
30. Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need Her2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology. 2003, 43: 354-362.
31. Cowell JK: Double minutes and homogeneously staining regions: gene amplification in mammalian cells. Annu Rev Genet. 1982, 16: 21-59. 10.1146/annurev.ge.16.120182.000321.
32. Sauer T, Wiedswang G, Boudjema G, Chirstensen H, Karesen R: Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?. APMIS. 2003, 111: 444-450. 10.1034/j.1600-0463.2003.t01-1-1110210.x.
33. Sidoni A, Cavaliere A, Belleza G, Scheibel M, Bucciarelli E: Breast cancer in young women: clinicopathologial features and biological specificity. Breast. 2003, 12: 247-250. 10.1016/S0960-9776(03)00095-X.
34. Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials?. J Natl Cancer Inst Monogr. 1994, 16: 35-42.
35. Hoff ER, Tubbs RR, Myles JL, Procop GW: Her2/neu amplification in breast cancer: stratification of tumor type and grade. Am J Clin Pathol. 2002, 117: 916-921. 10.1309/4NTU-N6K4-F8JF-EWRX.